Blood Advances (Dec 2017)

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

  • Jordan K. Schaefer,
  • Suman L. Sood,
  • Brian Haymart,
  • Xiaokui Gu,
  • Xiaowen Kong,
  • Eva Kline-Rogers,
  • Steven Almany,
  • Jay Kozlowski,
  • Gregory D. Krol,
  • Scott Kaatz,
  • James B. Froehlich,
  • Geoffrey D. Barnes

Journal volume & issue
Vol. 1, no. 26
pp. 2536 – 2540

Abstract

Read online

Abstract: Clinical factors and patient preferences are important for selecting oral anticoagulants for venous thromboembolism (VTE) and atrial fibrillation (AF). The relative association of sociodemographic factors with anticoagulant use is unknown. We evaluated a prospective cohort to compare sociodemographic variables in patients who continued on warfarin for AF or VTE to those who transitioned to 1 of the direct oral anticoagulants (DOACs). Adult patients, newly started on warfarin, were enrolled through 6 anticoagulation clinics across Michigan. Of 8468 patients, 53.3% had AF, 45.6% had VTE, and 1.1% had both. Of these, 696 (8.2%) switched from warfarin to a DOAC. There were no significant differences between switchers and nonswitchers for percentage of time with a therapeutic international normalized ratio on warfarin, urban-rural residence status, or health insurance. Switchers were more often white (83.3% vs 77.7%; P < .001), partnered (67.3% vs 59.2%; P < .001), or resided in a zip code with a higher median household income (P < .001). The results show that sociodemographic factors, such as race, partnered status, and income are associated with a patient's likelihood of switching to a DOAC vs remaining on warfarin therapy. Although clinical factors predominate, the reason for, and impact of, these observed variations in care requires further investigation.